Industry News Sponsored by
Quick Med Technologies and BASF have signed an agreement that allows Quick Med to use BASF's antiaging technology. According to BASF, the agreement will help it market its product. The agreement will end in December 2010.
The agreement involves BASF product MultiStat, a MMP inhibitors based on a family of matrix metalloproteinase (MMP) inhibitors - compounds that inhibit the production of MMPs. It consists of over 10 patented compounds and patented formulae for developing other compounds. However, BASF reportedly will only be using one. For more information, visit www.basf.com.